Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

Viking Therapeutics stock is down 52% over the trailing-12-month period. However, many Wall Street analysts remain ...

Currently trading with a volume of 1,145,610, the VKTX's price is down by -1.23%, now at $28.0. RSI readings suggest the ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...

Viking has found a manufacturing partner, removing a key overhang on the stock Viking Therapeutics Inc.'s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

We recently published a list of 10 Stocks Skyrocketing Today. In this article, we are going to take a look at where Viking ...

Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern. The ...

Is this a good time to buy shares of Viking Therapeutics, or could more of a decline be coming this year? The case for buying shares of Viking stock today Making a bullish case for Viking ...

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing contract, removing an overhang that has weighed on the stock for ...